Survival Benefit Plus Safety Profile Cements T-DM1 As Successor To Herceptin
This article was originally published in The Pink Sheet Daily
Executive Summary
Full results from the EMILIA study show that Roche’s antibody drug conjugate T-DM1 offers a 5.8 month survival benefit in mostly second-line advanced breast cancer. Reporting results in the New England Journal of Medicine, researchers highlight the effects regardless of line of therapy and the value of antibody drug conjugates in improving safety.
You may also be interested in...
India’s Piramal Healthcare, Fujifilm Diosynth Team Up For Booming Antibody Drug Conjugate Technology
The two companies look to combine complementary skills and offer services that promise to shorten development timelines.
Genentech Resubmits T-DM1 To FDA, This Time With An Overall Survival Benefit
The antibody drug conjugate showed a significant overall survival benefit in HER2-positive metastatic breast cancer in the EMILIA trial, the company announced.
Beyond Herceptin, Roche Readies Breast Cancer Successors, Braces For Biosimilars
Up-and-coming candidate T-DM1 shows an efficacy advantage in the Phase III EMILIA study, offers significantly better side effect profile and improved quality of life.